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speed were obtained using the Short Physical Performance Bat-
tery (SPPB) test. Pain and physical function were measured using
the WOMAC. Pearson partial correlations and linear regression
analyses adjusted for age, sex, and BMI were used to examine
the relationships among the variables of interest.
Results: A lower percent lower extremity fat (thigh + leg) was sig-
niﬁcantly associated with reduced pain (r=0.54; p=0.02), greater
physical function (r=0.66; p=0.003), and higher knee extensor
strength (r=-0.58, p=0.01). No signiﬁcant associations were found
between percent trunk fat and these measures. Greater knee ex-
tensor strength was also signiﬁcantly associated with reduced pain
(r=-0.42; p=0.02) and greater physical function (r=-0.46; p=0.01).
In addition, higher leg extensor power was signiﬁcantly associated
with faster chair rise time (r=-0.76; p=0.001) and walking speed
(r=0.54; p=0.03).
Conclusions: These results suggest that lower extremity fat, but
not trunk fat, and weak knee extensor strength and power may play
important roles in the increased pain and poor function common in
older adults with knee OA. Improving knee extensor strength and
reducing thigh fat may provide long-term improvements in pain
and function.
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Purpose: To evaluate the effects of analgesic treatment with
tapentadol extended release (ER) on health-related outcomes in
patients with moderate to severe chronic osteoarthritis knee pain
based on the EuroQol-5 Dimension (EQ-5D) and Western On-
tario and MacMaster Universities Osteoarthritis Index (WOMAC)
questionnaires.
Methods: In this double-blind phase 3 trial, patients randomized
in a 1:1:1 ratio received controlled, adjustable bid doses of tapen-
tadol ER (100-250 mg), oxycodone HCl controlled release (CR;
20-50 mg), or placebo over a 12-week maintenance period, pre-
ceded by a 3-week titration period. Patients completed EQ-5D
(evaluates mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) and WOMAC (evaluates pain, disability, and
joint stiffness) questionnaires at baseline and at speciﬁed study
visits.
Results: Of 1,030 patients who were randomized, 1,023 patients
were evaluable for efﬁcacy. At endpoint, the change from base-
line in the EQ-5D health status index was signiﬁcantly greater
with tapentadol ER than with oxycodone CR or placebo, indicat-
ing a greater improvement in health status (least squares mean
difference [LSMD] between tapentadol ER and oxycodone CR,
0.1 [95% conﬁdence interval (CI), 0.03 to 0.10; P<0.001]; LSMD
between tapentadol ER and placebo, 0.1 [95% CI, 0.02 to 0.09;
P=0.004]). Differences between oxycodone CR and placebo were
not statistically signiﬁcant (LSMD, -0.0 [95% CI, -0.05 to 0.02;
P=0.449]). At endpoint, mean changes in WOMAC global scores
were signiﬁcantly improved from baseline for both tapentadol ER
and oxycodone CR compared with placebo (LSMD vs placebo for
tapentadol ER, -0.2 [95% CI, -0.36 to -0.06; P=0.005]; LSMD vs
placebo for oxycodone CR, -0.2 [95% CI, -0.34 to -0.01; P=0.038]).
Treatment-emergent adverse events occurred in 61.1%, 75.9%,
and 87.4% of patients in the placebo (n=337), tapentadol ER
(n=344), and oxycodone CR (n=342) groups, respectively.
Conclusions: In patients with chronic osteoarthritis knee pain,
tapentadol ER (100-250 mg bid) signiﬁcantly improved the EQ-5D
health status index compared with placebo and oxycodone HCl CR
(20-50 mg bid), and both active treatments signiﬁcantly improved
WOMAC scores compared with placebo.
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Purpose: To evaluate patient- and physician-reported global as-
sessments of study medication and changes in health functional
status in a 1-year study of tapentadol extended release (ER) and
oxycodone controlled release (CR) for relief of moderate to severe
chronic low back pain or osteoarthritis pain.
Methods: Patients were randomized in a 4:1 ratio to receive
controlled, adjustable, bid doses of tapentadol ER (100-250 mg) or
oxycodone HCl CR (20-50 mg) for up to 1 year in this open-label
safety study. Overall effectiveness was assessed with separate
patient and physician global assessments of study medication (0
= “poor” to 4 = “excellent”) and the EuroQol 5 Dimension (EQ-5D)
questionnaire evaluating health functional status. Patients rated
each dimension (mobility, usual activities, pain/discomfort, self-
care, and anxiety/depression) of the EQ-5D on 3 levels, from
“no problems” to “extreme problems.” No statistical comparisons
between tapentadol ER and oxycodone CR were performed.
Results: Patients who received at least 1 dose of study medica-
tion (n = 1,117) were included in the safety analysis set; 1,095
of these patients were included in the efﬁcacy analysis set. Ad-
verse events led to study discontinuation in 22.7% of patients
in the tapentadol ER group and 36.8% of patients in the oxy-
codone CR group. At study endpoint, 75.1% (616/820) and 72.3%
(128/177) of patients treated with tapentadol ER and oxycodone
CR, respectively, rated their medication as “excellent,” “very good,”
or “good”; global physician rating results were similar (77.3%
[635/821] and 72.3% [128/177], respectively). Both groups showed
improvements in EQ-5D, as demonstrated by positive changes in
health status index. The mean (standard error of the mean [SEM])
change from baseline to study endpoint in health status index was
0.2 (0.01) for tapentadol ER and 0.2 (0.03) for oxycodone CR.
Higher percentages of patients receiving tapentadol ER than oxy-
codone CR reported “no problems” in mobility (42.6% vs 32.2%),
usual activities (38.7% vs 28.2%), and pain/discomfort (15.7% vs
8.7%) at study endpoint. The percentage of patients reporting “no
problems” in the remaining 2 dimensions of self-care (75.0% vs
73.2%) and anxiety/depression (60.7% vs 61.1%) were similar in
the tapentadol ER and oxycodone CR groups, respectively.
Conclusions: Long-term treatment with tapentadol ER (100-250
mg bid) improved physical functioning and was effective and well
tolerated for up to 1 year for relief of moderate to severe chronic
pain.
